Pay in 4 interest-free payments of $6.67 Learn more
Ships within 48 hours · Estimated delivery Oct 2 - Oct 7
Were now advancing toward Phase I clinical development and look forward to sharing more updates soon
In line with these findings, the modest proportion of patients which improved vasculogenic ED degree category included only those patients belonging to the baseline category of mildmoderate vasculogenic ED, which reached PSV values compatible with absence of ED
Tudor M, Jandric I, Marovic A, Gjurasin M, Perovic D, Radic B, et al
emerging evidence suggests that dalfampridine (at the same dose for walking speed improvement) may improve cognitive symptoms, but there is no approved pharmacologic therapy for cognitive deficiency in MS
US$ 25.56
US$ 23.42
US$ 25.88
US$ 25.75
US$ 23.43
US$ 27.44
US$ 20.26
